Skip to main content

Table 3 Meta-analysis of studies examining treatment uptake, treatment completion and SVR among people with Hepatitis C treated in a variety of community settings or specialist hospital care

From: A systematic review and meta-analysis of community and primary-care-based hepatitis C testing and treatment services that employ direct acting antiviral drug treatments

Inclusion Criteria

Treatment Uptake

Treatment Completion

SVR

 

No. Of studies

Heterogeneity

(I2)

Pooled estimate

(95% CI)

No. Of studies

Heterogeneity

(I2)

Pooled estimate (95% CI)

No. Of studies

Heterogeneity

(I2)

Pooled estimate (95% CI)

Opioid Treatment Centres

   

2

77.7%

91.9 (82.2–100)

3

0.0%

82.3 (77.8–86.8)

Integrated Health System (ECHO)

1

Not applicable

75.6 (68.0–83.2)

1

Not applicable

96.8 (93.2–100)

2

84.6%

81.3 (66.9–95.5)

Telemedicine

1

Not applicable

22.3 (15.8–28.8)

   

1

Not applicable

51.4 (34.8–68.0)

Primary Care

1

Not applicable

67.4 (53.9–80.9)

1

Not applicable

100 (97.95–100)

5

94.9%

74.4 (60.3–88.5)

Pharmacies / Pharmacist Clinics

1

Not applicable

66.67 (58.3–75.1)

   

2

89.0%

79.0 (79.2–98.9)

Specialist Care

2

0.0%

34.5 (31.79–37.29)

   

5

96.8%

73.46 (60.9–85.9)

  1. Abbreviations: CI, Confidence interval; SVR, Sustained virologic response
  2. a. Random-effects method used if I2 ≥ 30%